Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
| Keytruda | pembrolizumab | Gastric or gastroesophageal junction adenocarcinoma | Active | |||
| Veklury | remdesivir | COVID-19 in hospitalized patients | Active | |||
| Veklury | remdesivir | COVID-19 in non-hospitalized patients | Active | |||
| Ferinject | ferric carboxymaltose | Iron deficiency anemia | Received | |||
| Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Received | |||
| TBC | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Pending | |||
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Received | |||
| Velsipity | etrasimod | Ulcerative colitis | Active | |||
| Apretude | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active |
Last Updated : May 14, 2024